A new pharmacy startup has officially launched in Houston. Photo courtesy of Capsule

A health tech company has officially launched locally to serve as a digital pharmacy platform. The company is aiming to simplify the process for customers.

Capsule has launched in Houston to address access-challenged pharmacy deserts as well as allow for discreet delivery of frequently stigmatized medications. The company also prioritizes better communications than standard pharmacy service.

"Capsule's mission has always been to build a pharmacy that works for everyone," says Eric Kinariwala, founder and CEO of Capsule, in a news release. "We believe that the core pharmacy experience is fundamentally broken for the hundreds of millions of Americans who take medication regularly, so we set out to rebuild that experience from the inside out."

Capsule's custom software prevents common issues out-of-stock medications, long wait times, and lack of price transparency, as well as improves communications. Customers can sign up for the service — which includes same-day delivery within all of Harris County and parts of Chambers, Fort Bend, Galveston, and Montgomery counties — and have their physician send their prescriptions to Capsule. The company accepts all major insurance plans, including Medicare and Medicaid.

One problem that Capsule is attempting to solve is access to pharmaceuticals. According to the release, half of prescriptions in America go unfilled resulting in $300 billion in additional healthcare costs. One factor contributing to this problem is access.

"We know that there is a direct link between proximity to a pharmacy and prescription fill rates," Kinariwala says. "And the consequences of failing to fill vital prescriptions can be dire. Capsule is a part of the solution."

In Houston, pharmacy deserts disproportionately affect minorities. Over 40 percent of Hispanic residents and 70 percent of Black residents live a mile or more away from a pharmacy. According to USA Rx data, Harris County has 1.39 pharmacies per 10,000 residents, which is below the national average of 2.4.

"Capsule's long-term ambition is to create a hub where consumers can access all of their healthcare needs in a single, simple, holistic place," says Kinariwala. "We're doing that in a way that brings together everybody in healthcare versus trying to own all of those things ourselves. Just like you buy a cell phone and choose apps, people will be able to access Capsule's digital pharmacy, as well as a best-in-class curated set of products and services to meet all of their healthcare needs from within a single app."

Eric Kinariwala is the founder and CEO of Capsule. Photo courtesy of Capsule

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.